Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
A recent research study utilizing Nexalin's exclusive DIFS ™ 15 mA 77.5 Hz treatment system revealed significant and swift enhancements in anxiety and depression. These improvements were substantial in scale and were still noticeable during an 8-week check-up period following the treatment.